Savara Pharmaceuticals Garners $20,000,000 Series C Round

  • Feed Type
  • Date
    3/1/2016
  • Company Name
    Savara Pharmaceuticals
  • Mailing Address
    900 S. Capital of Texas Highway Austin, TX 78746 USA
  • Company Description
    Savara is a pharmaceutical company developing novel respiratory therapeutics utilizing our proprietary NanoCluster dry powder aerosol drug delivery platform.The aerosols are assembled directly from nanoparticles of an existing therapeutic and delivered via oral pulmonary or nasal routes using off-the-shelf dry powder inhalers.
  • Website
    http://www.savarapharma.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $20,000,000
  • Transaction Round
    Series C
  • Proceeds Purposes
    The new financing will help support the AeroVanc Phase 3 trial, and expanding our pipeline with other new drugs for serious and life-shortening rare respiratory diseases.
  • M&A Terms
  • Venture Investor
    Undisclosed

Trending on Xconomy